NL-OMON33661尚未招募不适用
Phase I/II study of combined treatment with AT-101, cisplatin and radiotherapy in patients with locally advanced head and neck cancer - AT-101, cisplatin and radiotherapy in head and neck cancer
Antoni van Leeuwenhoek Ziekenhuis0 个研究点目标入组 50 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99(—)
入选标准
- •Histologically proven squamous cell carcinoma of the head and neck
- •Oral cavity, oropharyngeal, or hypopharyngeal carcinoma
- •Inoperable TNM stage III/IV, M0
- •Patient must have measurable disease
- •Age > 18 years
- •Performance status WHO 0-2
- •No prior r adiation therapy to head and neck region
- •No prior cisplatin-based chemotherapy
- •Adequate laboratory results:
- •- WBC > 4.0 x 10E9/l
- •- platelets > 100 x 10E9/l
- •- calculated or 24 hour creatinine clearance > 50 ml/min
- •- ASAT/ALAT < 2.5 times upper limit of normal range
- •- Bilirubin < 1.5 x upper limit of institution's normal range
- •Willingness to use contraception by a method that is deemed effective by the Investigator throughout the treatment period and for at least 30 days following the last dose of therapy
- •Willing and able to undergo blood sampling for pharmacokinetics
- •Signed written informed consent before entry into study.
- •Entry criteria for translational research:
- •- Willing and able to undergo blood sampling, harvesting of buccal smears and tumor biopsy (mandatory)
- •- Willing and able to undergo skin biopsy and nuclear scanning (optional)
排除标准
- •Breast feeding or pregnancy
- •Uncontrolled arrhythmia
- •Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel, ulcerative colitis, inflammatory bowel disease, or partial or complete small bowel obstruction
- •Class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification.
- •Known active symptomatic fungal, bacterial and/or viral infection including active HIV
- •Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
研究者
相似试验
进行中(未招募)
不适用
Phase I/II Study of Combined Treatment with AT-101, Cisplatin and Radiotherapy in Patients with Locally Advanced Head and Neck CancerEUCTR2007-006120-36-NL50
已完成
2 期
Phase 2 Safety and Efficacy Study of AT-101 in Combination With Rituximab in Patients With Chronic Lymphocytic LeukemiaChronic Lymphocytic LeukemiaNCT00286780Ascenta Therapeutics19
尚未招募
2 期
Study of the effect of telmisartan on fibrosis in fatty liver diseaseon-alcoholic steatohepatitis (NASH)Non-alcoholic steatohepatitis (NASH)Inflammatory and Immune System - LiverACTRN12606000411549Professor Peter Angus40
招募中
不适用
A phase I study of conbination therapy with intratumorak administration of dendritic cells and radiation for far advanced esophageal cancerEsophageal cancerJPRN-UMIN000012218Chiba University6
进行中(未招募)
1 期
Study to observe efficacy and safety of AM-101 in patients with tinnitusacute peripheral tinnitus following traumatic cochlear injury or otitis mediaMedDRA version: 20.0Level: PTClassification code 10043882Term: TinnitusSystem Organ Class: 10013993 - Ear and labyrinth disordersEUCTR2012-004099-20-PLAuris Medical AG750
